myelodysplastic syndromes (MDS) | Page 118 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms.

Author(s): 
Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O.
Primary Author: 
Björkholm M
Journal Title: 
J Clin Oncol
Original Publication Date: 
May 2011

PURPOSE Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to develop

Bone Marrow Diseases: 

Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux

Author(s): 
Cheng KL, Brody J, Warshall CE, Sloand EM, Allen SL
Primary Author: 
Cheng KL
Journal Title: 
Leuk Res.
Original Publication Date: 
Apr 2010

No abstract available.

SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.

Author(s): 
Afable MG 2nd, Wlodarski M, Makishima H, Shaik M, Sekeres MA, Tiu RV, Kalaycio M, O'Keefe CL, Maciejewski JP
Primary Author: 
Afable MG 2nd
Journal Title: 
Blood
Original Publication Date: 
Apr 2011

In

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

Author(s): 
Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F
Primary Author: 
Garg R
Journal Title: 
Leukemia
Original Publication Date: 
Jul 2009

We investigated efficacy and safety of rabbit anti-thymocyte globulin (rATG),